Class Action Lawsuit Announced for Soleno Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy SLNO?
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for stock purchasers between March 26 and November 4, 2025, aiming to seek compensation for investors, highlighting the legal risks and potential financial losses faced by the company.
- Reasons for Lawsuit: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug clinical trials, including issues of fluid retention among participants, resulting in investor losses once the true information was disclosed, indicating a lack of transparency in the company's drug development processes.
- Investor Action Guidance: Investors can join the lawsuit by visiting a specified website or calling a hotline, reflecting the law firm's commitment to investor rights while also indicating uncertainty regarding Soleno's future commercial prospects.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.755
Low
75.00
Averages
110.50
High
125.00
Current: 33.755
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Announced for Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for stock purchasers between March 26 and November 4, 2025, reflecting investor concerns over potential safety issues.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno downplayed significant safety evidence related to its DCCR drug clinical trials, potentially exposing investors to greater risks and affecting the company's reputation and future market performance.
- Investor Losses: As the true details emerged, investors may have suffered damages, with the lawsuit offering compensation opportunities without out-of-pocket costs, indicating a legal avenue for affected investors to seek relief.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling such cases.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over DCCR Disclosures
- Class Action Filed: A securities class action lawsuit has been initiated against Soleno Therapeutics (NASDAQ:SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, following a 26% drop in share price triggered by disappointing DCCR (VYKAT™ XR) information released on November 5.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno systematically downplayed and concealed significant safety concerns related to DCCR's clinical trials, particularly issues of fluid retention, which could materially undermine the drug's commercial viability and investor confidence.
- Severe Market Reaction: Since August 15, 2025, when activist short seller Scorpion Capital raised concerns about Soleno's disclosures, the company's stock price has plummeted nearly 40% by November 5, indicating strong market apprehension regarding its commercial prospects.
- Ongoing Legal Investigation: Hagens Berman is investigating whether Soleno violated federal securities laws and is urging investors who suffered significant losses to submit their information to support potential legal actions.
See More
Faruqi & Faruqi Encourages Soleno Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Soleno Therapeutics, Inc., particularly for investors who purchased securities between March 26, 2025, and November 4, 2025, indicating possible legal risks for the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers and extension, demonstrating a commitment to investor rights and support.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in a federal securities class action is May 5, 2026, emphasizing the importance of timely action to protect their legal rights.
- Potential Impact Analysis: If the lawsuit is successful, it could negatively affect Soleno's stock price and company reputation, prompting investors to closely monitor the case's progress to make informed investment decisions.
See More
Class Action Filed Against Soleno Therapeutics for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Soleno Therapeutics and certain executives, alleging failure to disclose safety concerns related to the DCCR clinical trial from March 26 to November 4, 2025, potentially leading to investor losses.
- Inadequate Safety Disclosure: The complaint claims that Soleno systematically downplayed and concealed significant safety issues during the Phase 3 clinical trial of DCCR, including fluid retention in participants, which could severely diminish the drug's commercial viability.
- Potential Risk Implications: The undisclosed safety risks associated with DCCR could result in higher patient discontinuation rates, reduced prescriber willingness, and adverse regulatory actions, significantly impacting the company's market reputation and future sales potential.
- Investor Action Recommendations: Affected investors are encouraged to apply for lead plaintiff status by May 5, 2026, to seek compensation in the lawsuit, with the law firm operating on a contingency fee basis, thus minimizing financial risk for investors.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over Safety Concerns
- Class Action Initiation: Soleno Therapeutics is facing a class action lawsuit for failing to disclose safety risks associated with its DCCR drug, with the class period from March 26 to November 4, 2025, and investors have until May 5, 2026, to seek lead plaintiff status, which could significantly impact the company's reputation and stock price.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed significant safety issues during clinical trials, including fluid retention in participants, which raises serious questions about the drug's commercial viability and could attract regulatory scrutiny and legal repercussions.
- Stock Price Volatility: Following a critical report from Scorpion Capital, Soleno's stock price dropped nearly 12% over two trading days, and after a patient death linked to DCCR, the stock fell approximately 19%, indicating severe market concerns regarding the safety of the company's product.
- Law Firm Credentials: Robbins Geller Rudman & Dowd LLP, representing the plaintiffs, has recovered $8.4 billion for investors over the past five years, showcasing its strong track record in securities fraud and shareholder rights litigation, which may significantly influence the legal outcomes for Soleno.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes (NASDAQ: ASPI) continues after the Southern District of New York partially denied the defendants' motion to dismiss, indicating potential legal liabilities for the company and its executives, which could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may have long-term implications for its financial health.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting the potential impact of legal actions on corporate governance structures.
- Market Reaction: As the lawsuit progresses, investor confidence in the company's future may wane, leading to stock price volatility, reflecting the market's heightened scrutiny of the company's transparency and compliance.
See More
Class Action Lawsuit Announced for Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for stock purchasers between March 26 and November 4, 2025, reflecting investor concerns over potential safety issues.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno downplayed significant safety evidence related to its DCCR drug clinical trials, potentially exposing investors to greater risks and affecting the company's reputation and future market performance.
- Investor Losses: As the true details emerged, investors may have suffered damages, with the lawsuit offering compensation opportunities without out-of-pocket costs, indicating a legal avenue for affected investors to seek relief.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling such cases.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over DCCR Disclosures
- Class Action Filed: A securities class action lawsuit has been initiated against Soleno Therapeutics (NASDAQ:SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, following a 26% drop in share price triggered by disappointing DCCR (VYKAT™ XR) information released on November 5.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno systematically downplayed and concealed significant safety concerns related to DCCR's clinical trials, particularly issues of fluid retention, which could materially undermine the drug's commercial viability and investor confidence.
- Severe Market Reaction: Since August 15, 2025, when activist short seller Scorpion Capital raised concerns about Soleno's disclosures, the company's stock price has plummeted nearly 40% by November 5, indicating strong market apprehension regarding its commercial prospects.
- Ongoing Legal Investigation: Hagens Berman is investigating whether Soleno violated federal securities laws and is urging investors who suffered significant losses to submit their information to support potential legal actions.
See More
Faruqi & Faruqi Encourages Soleno Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Soleno Therapeutics, Inc., particularly for investors who purchased securities between March 26, 2025, and November 4, 2025, indicating possible legal risks for the company.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers and extension, demonstrating a commitment to investor rights and support.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in a federal securities class action is May 5, 2026, emphasizing the importance of timely action to protect their legal rights.
- Potential Impact Analysis: If the lawsuit is successful, it could negatively affect Soleno's stock price and company reputation, prompting investors to closely monitor the case's progress to make informed investment decisions.
See More
Class Action Filed Against Soleno Therapeutics for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Soleno Therapeutics and certain executives, alleging failure to disclose safety concerns related to the DCCR clinical trial from March 26 to November 4, 2025, potentially leading to investor losses.
- Inadequate Safety Disclosure: The complaint claims that Soleno systematically downplayed and concealed significant safety issues during the Phase 3 clinical trial of DCCR, including fluid retention in participants, which could severely diminish the drug's commercial viability.
- Potential Risk Implications: The undisclosed safety risks associated with DCCR could result in higher patient discontinuation rates, reduced prescriber willingness, and adverse regulatory actions, significantly impacting the company's market reputation and future sales potential.
- Investor Action Recommendations: Affected investors are encouraged to apply for lead plaintiff status by May 5, 2026, to seek compensation in the lawsuit, with the law firm operating on a contingency fee basis, thus minimizing financial risk for investors.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over Safety Concerns
- Class Action Initiation: Soleno Therapeutics is facing a class action lawsuit for failing to disclose safety risks associated with its DCCR drug, with the class period from March 26 to November 4, 2025, and investors have until May 5, 2026, to seek lead plaintiff status, which could significantly impact the company's reputation and stock price.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed significant safety issues during clinical trials, including fluid retention in participants, which raises serious questions about the drug's commercial viability and could attract regulatory scrutiny and legal repercussions.
- Stock Price Volatility: Following a critical report from Scorpion Capital, Soleno's stock price dropped nearly 12% over two trading days, and after a patient death linked to DCCR, the stock fell approximately 19%, indicating severe market concerns regarding the safety of the company's product.
- Law Firm Credentials: Robbins Geller Rudman & Dowd LLP, representing the plaintiffs, has recovered $8.4 billion for investors over the past five years, showcasing its strong track record in securities fraud and shareholder rights litigation, which may significantly influence the legal outcomes for Soleno.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes (NASDAQ: ASPI) continues after the Southern District of New York partially denied the defendants' motion to dismiss, indicating potential legal liabilities for the company and its executives, which could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may have long-term implications for its financial health.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting the potential impact of legal actions on corporate governance structures.
- Market Reaction: As the lawsuit progresses, investor confidence in the company's future may wane, leading to stock price volatility, reflecting the market's heightened scrutiny of the company's transparency and compliance.
See More
